Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. Sequential immune monitoring in patients with melanoma and renal cell carcinoma treated with high-dose interleukin-2: immune patterns and correlation with outcome.Cancer immunology, immunotherapy : CII · 2014
   Trial
2. Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response.Journal of translational medicine · 2014
   Trial
3. Melanoma immunotherapy.Cancer biology & therapy · 2014
   Review
4. Forkhead box proteins: tuning forks for transcriptional harmony.Nature reviews. Cancer · 2013
   Review
5. Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.The oncologist · 2013
   Review
6. Endostatin gene therapy stimulates upregulation of ICAM-1 and VCAM-1 in a metastatic renal cell carcinoma model.Cancer gene therapy · 2012
   Article
7. The prognostic impact of anti-cancer immune response: a novel classification of cancer patients.Seminars in immunopathology · 2011
   Review
8. Tumor immunosurveillance in human cancers.Cancer metastasis reviews · 2011
   Review
9. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors.Cancer biotherapy & radiopharmaceuticals · 2010
   Review
10. Melanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications.Journal of carcinogenesis · 2010
    Article
11. Adjuvant Immunotherapy and Radiation in the Management of High-risk Resected Melanoma.Ochsner journal · 2010
    Article
12. Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.Journal of translational medicine · 2009
    Article
13. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy.Journal of immunotherapy (Hagerstown, Md. : 1997)
    Article

Corrections and comments

• Comment on
  Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy.2009

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as